Structure-based Design of a Strain Transcending AMA1-RON2L Malaria Vaccine

Overview

Journal Nat Commun

Specialty Biology

Date 2023 Sep 2

PMID 37660103

Authors

Palak N Patel

Thayne H Dickey

Ababacar Diouf

Nichole D Salinas

Holly McAleese

Tarik Ouahes

Carole A Long

Kazutoyo Miura

Lynn E Lambert

Niraj H Tolia

Affiliations

Soon will be listed here.

Abstract

Apical membrane antigen 1 (AMA1) is a key malaria vaccine candidate and target of neutralizing antibodies. AMA1 binds to a loop in rhoptry neck protein 2 (RON2L) to form the moving junction during parasite invasion of host cells, and this complex is conserved among apicomplexan parasites. AMA1-RON2L complex immunization achieves higher growth inhibitory activity than AMA1 alone and protects mice against Plasmodium yoelii challenge. Here, three single-component AMA1-RON2L immunogens were designed that retain the structure of the two-component AMA1-RON2L complex: one structure-based design (SBD1) and two insertion fusions. All immunogens elicited high antibody titers with potent growth inhibitory activity, yet these antibodies did not block RON2L binding to AMA1. The SBD1 immunogen induced significantly more potent strain-transcending neutralizing antibody responses against diverse strains of Plasmodium falciparum than AMA1 or AMA1-RON2L complex vaccination. This indicates that SBD1 directs neutralizing antibody responses to strain-transcending epitopes in AMA1 that are independent of RON2L binding. This work underscores the importance of neutralization mechanisms that are distinct from RON2 blockade. The stable single-component SBD1 immunogen elicits potent strain-transcending protection that may drive the development of next-generation vaccines for improved malaria and apicomplexan parasite control.

Citing Articles

Potent AMA1-specific human monoclonal antibody against Plasmodium vivax Pre-erythrocytic and Blood Stages.

Winnicki A, Dietrich M, Yeoh L, Carias L, Roobsoong W, Drago C Nat Commun. 2024; 15(1):10556.

PMID: 39632799 PMC: 11618605. DOI: 10.1038/s41467-024-53848-4.

Multistage protective anti-CelTOS monoclonal antibodies with cross-species sterile protection against malaria.

Tang W, Salinas N, Kolli S, Xu S, Urusova D, Kumar H Nat Commun. 2024; 15(1):7487.

PMID: 39209843 PMC: 11362571. DOI: 10.1038/s41467-024-51701-2.

A broadly cross-reactive i-body to AMA1 potently inhibits blood and liver stages of Plasmodium parasites.

Angage D, Chmielewski J, Maddumage J, Hesping E, Caiazzo S, Lai K Nat Commun. 2024; 15(1):7206.

PMID: 39174515 PMC: 11341838. DOI: 10.1038/s41467-024-50770-7.

Malaria vaccines: a new era of prevention and control.

Duffy P, Gorres J, Healy S, Fried M Nat Rev Microbiol. 2024; 22(12):756-772.

PMID: 39025972 DOI: 10.1038/s41579-024-01065-7.

Structure-based design of a Plasmodium vivax Duffy-binding protein immunogen focuses the antibody response to functional epitopes.

Dickey T, McAleese H, Salinas N, Lambert L, Tolia N Protein Sci. 2024; 33(8):e5095.

PMID: 38988315 PMC: 11237555. DOI: 10.1002/pro.5095.

References

Thera M, Doumbo O, Coulibaly D, Laurens M, Kone A, Guindo A . Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial. PLoS One. 2010; 5(2):e9041. PMC: 2816207. DOI: 10.1371/journal.pone.0009041. View

Kusi K, Faber B, Riasat V, Thomas A, Kocken C, Remarque E . Generation of humoral immune responses to multi-allele PfAMA1 vaccines; effect of adjuvant and number of component alleles on the breadth of response. PLoS One. 2010; 5(11):e15391. PMC: 2972715. DOI: 10.1371/journal.pone.0015391. View

Polley S, Chokejindachai W, Conway D . Allele frequency-based analyses robustly map sequence sites under balancing selection in a malaria vaccine candidate antigen. Genetics. 2003; 165(2):555-61. PMC: 1462796. DOI: 10.1093/genetics/165.2.555. View

Payne R, Milne K, Elias S, Edwards N, Douglas A, Brown R . Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01. J Infect Dis. 2016; 213(11):1743-51. PMC: 4857475. DOI: 10.1093/infdis/jiw039. View

McCoy A, Grosse-Kunstleve R, Storoni L, Read R . Likelihood-enhanced fast translation functions. Acta Crystallogr D Biol Crystallogr. 2005; 61(Pt 4):458-64. DOI: 10.1107/S0907444905001617. View

Williams C, Headd J, Moriarty N, Prisant M, Videau L, Deis L . MolProbity: More and better reference data for improved all-atom structure validation. Protein Sci. 2017; 27(1):293-315. PMC: 5734394. DOI: 10.1002/pro.3330. View

Howell S, Kocken C, Thomas A, Blackman M . Proteolytic processing and primary structure of Plasmodium falciparum apical membrane antigen-1. J Biol Chem. 2001; 276(33):31311-20. DOI: 10.1074/jbc.M103076200. View

Dickey T, Gupta R, McAleese H, Ouahes T, Orr-Gonzalez S, Ma R . Design of a stabilized non-glycosylated Pfs48/45 antigen enables a potent malaria transmission-blocking nanoparticle vaccine. NPJ Vaccines. 2023; 8(1):20. PMC: 9938515. DOI: 10.1038/s41541-023-00619-9. View

Mitchell G, Thomas A, Margos G, Dluzewski A, Bannister L . Apical membrane antigen 1, a major malaria vaccine candidate, mediates the close attachment of invasive merozoites to host red blood cells. Infect Immun. 2003; 72(1):154-8. PMC: 343990. DOI: 10.1128/IAI.72.1.154-158.2004. View

10.

Spiegel H, Boes A, Kastilan R, Kapelski S, Edgue G, Beiss V . The stage-specific in vitro efficacy of a malaria antigen cocktail provides valuable insights into the development of effective multi-stage vaccines. Biotechnol J. 2015; 10(10):1651-9. DOI: 10.1002/biot.201500055. View

11.

Healer J, Murphy V, Hodder A, Masciantonio R, Gemmill A, Anders R . Allelic polymorphisms in apical membrane antigen-1 are responsible for evasion of antibody-mediated inhibition in Plasmodium falciparum. Mol Microbiol. 2004; 52(1):159-68. DOI: 10.1111/j.1365-2958.2003.03974.x. View

12.

Miura K, Herrera R, Diouf A, Zhou H, Mu J, Hu Z . Overcoming allelic specificity by immunization with five allelic forms of Plasmodium falciparum apical membrane antigen 1. Infect Immun. 2013; 81(5):1491-501. PMC: 3648006. DOI: 10.1128/IAI.01414-12. View

13.

Dutta S, Lalitha P, Ware L, Barbosa A, Moch J, Vassell M . Purification, characterization, and immunogenicity of the refolded ectodomain of the Plasmodium falciparum apical membrane antigen 1 expressed in Escherichia coli. Infect Immun. 2002; 70(6):3101-10. PMC: 127972. DOI: 10.1128/IAI.70.6.3101-3110.2002. View

14.

Lamarque M, Besteiro S, Papoin J, Roques M, Vulliez-Le Normand B, Morlon-Guyot J . The RON2-AMA1 interaction is a critical step in moving junction-dependent invasion by apicomplexan parasites. PLoS Pathog. 2011; 7(2):e1001276. PMC: 3037350. DOI: 10.1371/journal.ppat.1001276. View

15.

Gautier A, Hinner M . Preface. Site-specific protein labeling. Methods Mol Biol. 2015; 1266:v-viii. DOI: 10.1007/978-1-4939-2272-7. View

16.

Triglia T, HEALER J, Caruana S, Hodder A, Anders R, Crabb B . Apical membrane antigen 1 plays a central role in erythrocyte invasion by Plasmodium species. Mol Microbiol. 2000; 38(4):706-18. DOI: 10.1046/j.1365-2958.2000.02175.x. View

17.

Tonkin M, Roques M, Lamarque M, Pugniere M, Douguet D, Crawford J . Host cell invasion by apicomplexan parasites: insights from the co-structure of AMA1 with a RON2 peptide. Science. 2011; 333(6041):463-7. DOI: 10.1126/science.1204988. View

18.

Camponovo F, Campo J, Le T, Oberai A, Hung C, Pablo J . Proteome-wide analysis of a malaria vaccine study reveals personalized humoral immune profiles in Tanzanian adults. Elife. 2020; 9. PMC: 7386907. DOI: 10.7554/eLife.53080. View

19.

Pizarro J, Vulliez-Le Normand B, Chesne-Seck M, Collins C, Withers-Martinez C, Hackett F . Crystal structure of the malaria vaccine candidate apical membrane antigen 1. Science. 2005; 308(5720):408-11. DOI: 10.1126/science.1107449. View

20.

Polley S, Conway D . Strong diversifying selection on domains of the Plasmodium falciparum apical membrane antigen 1 gene. Genetics. 2001; 158(4):1505-12. PMC: 1461755. DOI: 10.1093/genetics/158.4.1505. View